Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 zanidatamab ± tislelizumab plus chemotherapy in HER2-positive unresectable or metastatic gastroesophageal adenocarcinoma
jRCT2061230026Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of zanidatamab in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Started Aug 2023; status: active, not recruiting.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2061230026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230026.